Real-world data after first-line osimertinib
Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib in patients with EGFRm advanced NSCLC.
